HER2-Positive Breast Cancer Market Report 2026
Download Free Sample Buy Now
HER2-Positive Breast Cancer Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

HER2-Positive Breast Cancer Market Report 2026

Global Outlook – By Treatment Type (Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types), By Route Of Administration (Parenteral, Oral, Other Routes Of Administrations), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End User) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

HER2-Positive Breast Cancer Market Overview

• HER2-Positive Breast Cancer market size has reached to $10.93 billion in 2025

• Expected to grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%

• Growth Driver: Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market

• Market Trend: Innovative Therapies In The HER2-Positive Breast Cancer Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Positive Breast Cancer Market?

HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity.

The main types of treatments for HER2-positive breast cancer are targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other treatment types. Targeted therapy is a cancer treatment that precisely attacks specific molecules, such as proteins or genes driving cancer growth, while sparing normal cells. These drugs are administered through various routes, including parenteral, oral, and other route of administrations. It is distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and is used by various end users including hospitals, homecare, specialty clinics, and others.

HER2-Positive Breast Cancer Market Global Report 2026 Market Report bar graph

What Is The HER2-Positive Breast Cancer Market Size and Share 2026?

The her2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.93 billion in 2025 to $11.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing identification of her2-positive cases, expansion of targeted oncology drug approvals, growth in hospital oncology infrastructure, availability of monoclonal antibody therapies, rising clinical trial activity.

What Is The HER2-Positive Breast Cancer Market Growth Forecast?

The her2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of next-generation her2 inhibitors, expansion of biosimilar penetration, growing demand for precision oncology treatments, rising investment in targeted cancer research, increasing focus on improving survival outcomes. Major trends in the forecast period include increasing adoption of her2-targeted antibody therapies, growing use of antibody-drug conjugates, expansion of companion diagnostic testing, rising focus on early-stage targeted treatment, enhanced integration of combination therapy approaches.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global HER2-Positive Breast Cancer Market Segmentation

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Is The Driver Of The HER2-Positive Breast Cancer Market?

The strong adoption of immunotherapy is expected to propel the growth of the HER2-positive breast cancer market going forward. Immunotherapy refers to a medical treatment that enhances or modifies the immune system's natural ability to fight diseases, such as cancer, infections, and autoimmune disorders. The adoption of immunotherapy is attributed to its capability to enhance the immune system's ability to identify and eliminate cancer cells, providing better efficacy and fewer side effects than conventional treatments. Immunotherapy aids HER2-positive breast cancer by enhancing the body's immune system to recognize and attack HER2-overexpressing cancer cells, improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, according to the American Association for Cancer Research, a US-based organization, in 2023, the FDA has approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the strong adoption of immunotherapy is driving the growth of the HER2-positive breast cancer industry.

Key Players In The Global HER2-Positive Breast Cancer Market

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

Global HER2-Positive Breast Cancer Market Trends and Insights

Major companies operating in the HER2-positive breast cancer market are focused on developing innovative therapies, such as her2-directed antibody-drug conjugates (ADCs), to streamline and enhance the treatment process for patients. HER2-directed antibody-drug conjugates (ADCs) are targeted cancer therapies that link an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which delivers a cytotoxic drug directly to HER2-positive cancer cells, offering a more targeted and effective treatment for patients.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The HER2-Positive Breast Cancer Market?

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired rights to Zion’s lead program, ZN-A-1041, for an undisclosed amount. The acquisition aims to advance the development and commercialization of Zion Pharma's ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor, for treating brain metastases in HER2-positive breast cancer patients. Zion Pharma Limited, a China-based biotechnology company that specializes in providing drugs to treat HER2-positive breast cancer.

Regional Outlook

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Positive Breast Cancer Market?

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HER2-Positive Breast Cancer Market Report 2026?

The her2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-positive breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

HER2-Positive Breast Cancer Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $11.7 billion
Revenue Forecast In 2035 $15.23 billion
Growth Rate CAGR of 7.1% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Treatment Type, Route Of Administration, Distribution Channel, End User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. HER2-Positive Breast Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global HER2-Positive Breast Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. HER2-Positive Breast Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global HER2-Positive Breast Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Her2-Targeted Antibody Therapies

4.2.2 Growing Use Of Antibody-Drug Conjugates

4.2.3 Expansion Of Companion Diagnostic Testing

4.2.4 Rising Focus On Early-Stage Targeted Treatment

4.2.5 Enhanced Integration Of Combination Therapy Approaches

5. HER2-Positive Breast Cancer Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Clinics

5.3 Specialty Cancer Centers

5.4 Research Institutes

5.5 Ambulatory Oncology Centers

6. HER2-Positive Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global HER2-Positive Breast Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global HER2-Positive Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global HER2-Positive Breast Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global HER2-Positive Breast Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global HER2-Positive Breast Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global HER2-Positive Breast Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. HER2-Positive Breast Cancer Market Segmentation

9.1. Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

9.2. Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Parenteral, Oral, Other Routes Of Administrations

9.3. Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

9.4. Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Homecare, Specialty Clinics, Other End User

9.5. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

9.6. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

9.7. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

9.8. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

9.9. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

10. HER2-Positive Breast Cancer Market Regional And Country Analysis

10.1. Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific HER2-Positive Breast Cancer Market

11.1. Asia-Pacific HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China HER2-Positive Breast Cancer Market

12.1. China HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India HER2-Positive Breast Cancer Market

13.1. India HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan HER2-Positive Breast Cancer Market

14.1. Japan HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia HER2-Positive Breast Cancer Market

15.1. Australia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia HER2-Positive Breast Cancer Market

16.1. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea HER2-Positive Breast Cancer Market

17.1. South Korea HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan HER2-Positive Breast Cancer Market

18.1. Taiwan HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia HER2-Positive Breast Cancer Market

19.1. South East Asia HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe HER2-Positive Breast Cancer Market

20.1. Western Europe HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK HER2-Positive Breast Cancer Market

21.1. UK HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany HER2-Positive Breast Cancer Market

22.1. Germany HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France HER2-Positive Breast Cancer Market

23.1. France HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy HER2-Positive Breast Cancer Market

24.1. Italy HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain HER2-Positive Breast Cancer Market

25.1. Spain HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe HER2-Positive Breast Cancer Market

26.1. Eastern Europe HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia HER2-Positive Breast Cancer Market

27.1. Russia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America HER2-Positive Breast Cancer Market

28.1. North America HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA HER2-Positive Breast Cancer Market

29.1. USA HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada HER2-Positive Breast Cancer Market

30.1. Canada HER2-Positive Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America HER2-Positive Breast Cancer Market

31.1. South America HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil HER2-Positive Breast Cancer Market

32.1. Brazil HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East HER2-Positive Breast Cancer Market

33.1. Middle East HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa HER2-Positive Breast Cancer Market

34.1. Africa HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. HER2-Positive Breast Cancer Market Regulatory and Investment Landscape

36. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

36.1. HER2-Positive Breast Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. HER2-Positive Breast Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. HER2-Positive Breast Cancer Market Company Profiles

36.3.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

38. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

40. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

40.1 HER2-Positive Breast Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 HER2-Positive Breast Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 HER2-Positive Breast Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global HER2-Positive Breast Cancer Market, Overview Of Key Products - Product Examples
  • Table 2: Global HER2-Positive Breast Cancer Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global HER2-Positive Breast Cancer Market, Supply Chain Analysis
  • Table 4: Global HER2-Positive Breast Cancer Market, Major Raw Material Providers
  • Table 5: Global HER2-Positive Breast Cancer Market, Major Resource Providers
  • Table 6: Global HER2-Positive Breast Cancer Market, Major Manufacturers (Suppliers)
  • Table 7: Global HER2-Positive Breast Cancer Market, Major Distributors And Channel Partners
  • Table 8: Global HER2-Positive Breast Cancer Market, Key Technologies & Future Trends
  • Table 9: Global HER2-Positive Breast Cancer Market, Major Trends
  • Table 10: Global HER2-Positive Breast Cancer Market, Major End Users
  • Table 11: Global HER2-Positive Breast Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global HER2-Positive Breast Cancer Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global HER2-Positive Breast Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global HER2-Positive Breast Cancer Market - TAM, US$ Billion, 2025
  • Table 15: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 98: Global HER2-Positive Breast Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 99: Global HER2-Positive Breast Cancer Market - Company Scoring Matrix
  • Table 100: F. Hoffmann-La Roche AG Financial Performance
  • Table 101: AstraZeneca plc Financial Performance
  • Table 102: Novartis International AG Financial Performance
  • Table 103: Pfizer Inc. Financial Performance
  • Table 104: Eli Lilly and Company Financial Performance
  • Table 105: Global HER2-Positive Breast Cancer Market, Competitive Benchmarking (In USD Billions)
  • Table 106: Global HER2-Positive Breast Cancer Market, Competitive Dashboard
  • Table 107: Global HER2-Positive Breast Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 108: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Table 109: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Table 110: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global HER2-Positive Breast Cancer Market, Overview Of Key Products - Product Examples
  • Figure 2: Global HER2-Positive Breast Cancer Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global HER2-Positive Breast Cancer Market, Supply Chain Analysis
  • Figure 4: Global HER2-Positive Breast Cancer Market, Major Raw Material Providers
  • Figure 5: Global HER2-Positive Breast Cancer Market, Major Resource Providers
  • Figure 6: Global HER2-Positive Breast Cancer Market, Major Manufacturers (Suppliers)
  • Figure 7: Global HER2-Positive Breast Cancer Market, Major Distributors And Channel Partners
  • Figure 8: Global HER2-Positive Breast Cancer Market, Key Technologies & Future Trends
  • Figure 9: Global HER2-Positive Breast Cancer Market, Major Trends
  • Figure 10: Global HER2-Positive Breast Cancer Market, Major End Users
  • Figure 11: Global HER2-Positive Breast Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global HER2-Positive Breast Cancer Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global HER2-Positive Breast Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global HER2-Positive Breast Cancer Market - TAM, US$ Billion, 2025
  • Figure 15: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Taiwan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: South East Asia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 98: Global HER2-Positive Breast Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 99: Global HER2-Positive Breast Cancer Market - Company Scoring Matrix
  • Figure 100: F. Hoffmann-La Roche AG Financial Performance
  • Figure 101: AstraZeneca plc Financial Performance
  • Figure 102: Novartis International AG Financial Performance
  • Figure 103: Pfizer Inc. Financial Performance
  • Figure 104: Eli Lilly and Company Financial Performance
  • Figure 105: Global HER2-Positive Breast Cancer Market, Competitive Benchmarking (In USD Billions)
  • Figure 106: Global HER2-Positive Breast Cancer Market, Competitive Dashboard
  • Figure 107: Global HER2-Positive Breast Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 108: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Figure 109: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Figure 110: Global, HER2-Positive Breast Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Triple Negative Breast Cancer Market Report 2026 - Global Outlook – By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Surgery, Radiation Therapy, Other Treatment Types), By Type Of Test (Imaging Technique...

Breast Cancer Diagnostics Market Report 2026 - Global Outlook – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridizati...

Breast Cancer Drugs Market Report 2026 - Global Outlook – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Othe...

Metastatic HR+/HER2- Breast Cancer Market Report 2026 - Global Outlook – By Drugs (Paclitaxel, Tamoxifen, Docetaxel, Other Drugs), By Treatment (Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal M...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026 - Global Outlook – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Tes...

Metastatic Breast Cancer Treatment Market Report 2026 - Global Outlook – By Therapy Type (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), By Molecule Type (Monoclonal Antibod...

Cancer Biomarker Market Report 2026 - Global Outlook – By Biomarker Type (Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types), By Profiling Technologies (Omics Technologies, Immunoassay, Bioinformatics, Cytoge...

Next-Generation Gynecological Cancer Diagnostics Market Report 2026 - Global Outlook – By Cancer Type (Cervical Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer), By Function (Therapeutic Monitoring,...

Frequently Asked Questions

The HER2-Positive Breast Cancer market was valued at $10.93 billion in 2025, increased to $11.7 billion in 2026, and is projected to reach $15.23 billion by 2030.

The global HER2-Positive Breast Cancer market is expected to grow at a CAGR of 6.8% from 2026 to 2035 to reach $15.23 billion by 2035.

Some Key Players in the HER2-Positive Breast Cancer market Include, F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc. .

Major trend in this market includes: Innovative Therapies In The HER2-Positive Breast Cancer Market. For further insights on this market. request a sample here

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us